Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Pricing Impact (% pts cc): -1.0% in FY2025.
Latest, FY2025
-1.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
2 years
Since FY2023
Sources
2
Documents cited below
Where the FY2025 figure comes from
“Net sales were USD 54.5 billion (+8%, +8% cc), with volume contributing 15 percentage points to growth. Generic competition had a negative impact of 6 percentage points, pricing had a negative impact of 1 percentage point and currency had no impact.”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K (Operating Review).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pricing Impact (% pts cc) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1.0% | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | -2.0% | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Cite this data
StockData. (2026). Novartis Pricing Impact (% pts cc) (%), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/bridge-pricing-pp
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.